Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 65.87 Bil Enterprise Value: 59.05 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Piper Sandler Healthcare Conference Transcript

Nov 29, 2023 / 03:00PM GMT
Release Date Price: MXN594.48
Christopher Joseph Raymond
Piper Sandler & Co., Research Division - MD & Senior Research Analyst

Okay. I think we're going to go ahead and get started. Thanks, everybody, for being here. My name is Chris Raymond. I'm one of the senior biotech analysts at Piper Sandler.

Pleased to introduce our next presenter, which is Ultragenyx. Emil Kakkis is with us, the President and CEO. We've got about 25 or so minutes for an informal Q&A just to go over sort of the format. I'd like to keep this as informal as possible. So if anybody in the audience has any questions, just raise your hand. Let me know, I'll make sure your question gets asked and answered.

Before we dive into Q&A, Emil, for the folks who might not be completely versed on the Ultragenyx story, maybe just walk us through the elevator pitch, if you will, and then I'll dive into my questions.

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director

Sure, Chris. Happy be here with you again. Ultragenyx is now 13 years in from founding. And in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot